



OPEN

# Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil

Thiago Cerqueira-Silva <sup>1,2,11</sup>, Srinivasa Vittal Katikireddi <sup>3,4,11</sup>, Vinicius de Araujo Oliveira <sup>2,5</sup>, Renzo Flores-Ortiz <sup>5</sup>, Juracy Bertoldo Júnior<sup>2,5</sup>, Enny S. Paixão <sup>6</sup>, Chris Robertson<sup>4,7</sup>, Gerson O. Penna <sup>8</sup>, Guilherme L. Werneck <sup>9</sup>, Maurício L. Barreto<sup>2,5</sup>, Neil Pearce <sup>6</sup>, Aziz Sheikh <sup>10,12</sup>, Manoel Barral-Netto<sup>1,2,5,12</sup> and Viviane S. Boaventura <sup>1,2,12</sup> ✉

**There is considerable interest in the waning of effectiveness of coronavirus disease 2019 (COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national Brazilian databases, we undertook a test-negative design study involving almost 14 million people (~16 million tests) to estimate VE of CoronaVac over time and VE of BNT162b2 booster vaccination against RT-PCR-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes (hospitalization or death). Compared with unvaccinated individuals, CoronaVac VE at 14–30 d after the second dose was 55.0% (95% confidence interval (CI): 54.3–55.7) against confirmed infection and 82.1% (95% CI: 81.4–82.8) against severe outcomes. VE decreased to 34.7% (95% CI: 33.1–36.2) against infection and 72.5% (95% CI: 70.9–74.0) against severe outcomes over 180 d after the second dose. A BNT162b2 booster, 6 months after the second dose of CoronaVac, improved VE against infection to 92.7% (95% CI: 91.0–94.0) and VE against severe outcomes to 97.3% (95% CI: 96.1–98.1) 14–30 d after the booster. Compared with younger age groups, individuals 80 years of age or older had lower protection after the second dose but similar protection after the booster. Our findings support a BNT162b2 booster vaccine dose after two doses of CoronaVac, particularly for the elderly.**

Vaccination is an essential strategy to mitigate the effects of the coronavirus disease 2019 (COVID-19) pandemic. Inactivated virus vaccines are among the most widely used worldwide, and they are especially useful for low- and middle-income countries given their less stringent cold chain requirements for preservation and transportation and their lower costs compared to mRNA vaccines. The most commonly used inactivated virus vaccines are CoronaVac, Sinopharm and Bharat Biotech, with more than 4.5 billion doses of these vaccines having been delivered worldwide as of 14 December 2021 (ref. <sup>1</sup>).

Initial evaluations of VE of inactivated virus vaccines have demonstrated high protection against severe disease, especially in the non-elderly population<sup>2,3</sup>. However, even in younger individuals, VE is lower compared to other vaccine types<sup>3</sup>. There is growing evidence of waning protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes for mRNA-based vaccines coding for the spike protein<sup>4,5</sup>. Neutralizing antibody responses wane after CoronaVac vaccination<sup>6,7</sup>, but the durability of VE against clinical outcomes is unknown and has important implications for informing decisions about vaccine boosters.

In Brazil, COVID-19 vaccination started on 18 January 2021. The Brazilian COVID-19 vaccination program now includes CoronaVac (Sinovac Biotech), ChAdOx1 (AstraZeneca), Ad26.COV2.S (Janssen) and BNT162b2 (Pfizer-BioNTech) vaccines for

primary immunization. All doses administered in Brazil were provided by the Ministry of Health. CoronaVac was the first COVID-19 vaccine to be offered and was the most widely used among individuals 60 years of age and older. By the end of June, most elderly individuals had received two doses of CoronaVac (primary vaccination series)<sup>3</sup>. Six months after completing a primary vaccination series, individuals become eligible for a booster dose, preferentially with BNT162b2 vaccine<sup>8</sup>.

Using Brazilian national data, we evaluated the effectiveness of two doses of CoronaVac against confirmed SARS-CoV-2 infection and severe COVID-19 outcomes (hospitalization and death) from time since vaccination compared to unvaccinated individuals, using a test-negative design (TND) case-control study. We also estimated the effectiveness of the BNT162b2 mRNA vaccine as a booster dose, which has been the most widely used booster vaccine in Brazil. A summary of the main findings, limitations and policy implications of the study is provided in Table 1.


## Results

From 24 February 2020 to 11 November 2021, 23,476,273 individuals were tested for suspected SARS-CoV-2 infection, with a peak of severe outcomes between February 2021 and April 2021 (Extended Data Figs. 1–4). Among the 13.3 million tests not eligible for this study, 8.8 million were performed before the vaccination campaign in Brazil (18 January 2021). These tests were used only to access the

<sup>1</sup>LIB and LEITV Laboratories, Instituto Gonçalo Moniz, Salvador, Brazil. <sup>2</sup>Universidade Federal de Bahia (UFBA), Salvador, Brazil. <sup>3</sup>MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, Glasgow, UK. <sup>4</sup>Public Health Scotland, Glasgow, UK. <sup>5</sup>Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz, Salvador, Brazil. <sup>6</sup>London School of Hygiene and Tropical Medicine, London, UK. <sup>7</sup>Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK. <sup>8</sup>Núcleo de Medicina Tropical, Universidade de Brasília, Escola Fiocruz de Governo, Fiocruz, Brazil. <sup>9</sup>Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil. <sup>10</sup>Usher Institute, University of Edinburgh, Edinburgh, UK. <sup>11</sup>These authors contributed equally: Thiago Cerqueira-Silva, Srinivasa Vittal Katikireddi. <sup>12</sup>These authors jointly supervised this work: Aziz Sheikh, Manoel Barral-Netto, Viviane S. Boaventura. ✉e-mail: [viviane.boaventura@fiocruz.br](mailto:viviane.boaventura@fiocruz.br)


**Table 1 | Policy summary**

<b>Background</b>	Protection of mRNA-based and viral vector-based vaccines against infection, hospital admission and death due to SARS-CoV-2 declines over time, with these effects being most pronounced among the elderly. It is unclear whether similar patterns of waning are seen for inactivated whole-cell COVID-19 vaccines. In Brazil, CoronaVac has been administered since January 2021, and most older individuals received this vaccine. In September 2021, a booster vaccine dose program began, this being offered to individuals 6 months after completing their primary vaccination schedule. The BNT162b2 mRNA vaccine was primarily used for boosters.
<b>Main findings and limitations</b>	Analyzing linked national Brazilian databases, we observed that protection against infection, hospitalization and death fell over time after the primary vaccination schedule with CoronaVac, with particularly marked decreases in older individuals. The decline in VE occurred in the context of Gamma and Delta being the dominant viral variants. A BNT162b2 mRNA booster dose restored VE against infection and severe outcomes in all age groups.  Some limitations include the short length of follow-up after the booster dose and analyzing only BNT162b2 mRNA boosters. Changes in transmission rates and in the viral variants circulating during the study period might have influenced VE over the time.
<b>Policy implications</b>	Our findings provide evidence for using a heterologous booster of the BNT162b2 mRNA vaccine after completing the primary CoronaVac immunization schedule to achieve a sufficient level of protection against infection and severe outcomes. Continuous monitoring of VE will be necessary to evaluate the duration of protection after the booster dose.

**Fig. 1 | Flowchart of the study population from surveillance databases and selection of cases and controls.** \*Antigen or RT-PCR—sample collected 10 or fewer days after symptom onset.

status of the previous infections of the study participants and were not used in the main analysis. Additionally, 2.6 million tests were performed in individuals younger than 18 years of age, an age group

not included in the present study. In the study period—18 January 2021 to 11 November 2021—a total of 14,362,482 individuals were considered eligible and were tested either by rapid antigen test or



**Fig. 2 | Number of cases and controls, by week, during the study period, stratified by vaccination status (unvaccinated, vaccinated with CoronaVac and vaccinated with other vaccines).** Green, individuals with at least one dose of CoronaVac. Blue, individuals with at least one dose of any other vaccine (BNT162b2, ChAdOx1 or Ad26.COV2.S). Red, individuals unvaccinated.

RT-PCR, of whom 7,314,318 individuals (7,747,121 tests) were tested by RT-PCR (Fig. 1).

Most individuals (71.4%) were unvaccinated at the time of testing, but there was a sharp decrease in the number of tests per week after June 2021 and a gradual transition to more vaccinated individuals being tested, corresponding to the increase in the cumulative uptake of vaccination in Brazil (Fig. 2 and Supplementary Fig. 1). A total of 913,052 individuals were vaccinated with CoronaVac, of whom 7,863 received a booster dose of BNT162b2. Most of these individuals (93.4%) were tested within 30 d after the booster dose (Table 2, Extended Data Tables 1 and 2 and Extended Data Figs. 5 and 6).

**Main analyses.** Compared to unvaccinated individuals, VE against infection and severe outcomes progressively decreased with time from the second CoronaVac dose and increased after the BNT162b2 booster dose (Tables 3 and 4). Waning protection was more marked for infection than for severe COVID-19 outcomes. Between 14–30 d and more than 180 d after the second dose, VE against infection decreased from 55.0% (95% confidence interval (CI): 54.3–55.7) to 34.7% (95% CI: 33.1–36.2). There was an increase in VE 7–13 d after BNT162b2 booster vaccination (80.2%, 95% CI: 77.0–82.9), reaching a peak at 14–30 d (92.7%, 95% CI: 91.0–94.0). A decrease in VE against infection was observed 30 d after the booster dose (82.6%, 95% CI: 76.9–86.9); however, this group represents only 6.6% of individuals who received a booster dose in our sample (Table 3 and Extended Data Table 1).

Estimated VE for severe disease also decreased from 82.1% (95% CI: 81.4–82.8) at 14–30 d to 72.5% (95% CI: 70.9–74.0) more than

180 d after the second CoronaVac dose (Table 3). VE then increased gradually after the BNT162b2 booster dose to 80.6% (95% CI: 76.4–84.0) at 0–6 d, 97.3% (95% CI: 96.1–98.1) at 14–30 d and 96.8% (95% CI: 94.1–98.3) 30 d after booster vaccination (Table 4).

**Subgroup analyses by age and outcome.** We also conducted an analysis by age groups of VE after CoronaVac and VE after the BNT162b2 booster. The comparison for VE estimates was unvaccinated individuals. In individuals 80 years of age or older, the pattern of waning was more accentuated. The VE against infection fell from 50.3% (95% CI: 46.8–53.6) at 14–30 d to 10.1% (95% CI: 1.1–18.3) at more than 180 d after the second dose of CoronaVac. After the booster dose of BNT162b2, VE against infection reached 82.0% (95% CI: 75.0–87.0) at 14–30 d and 66.4% (95% CI: 49.6–77.5) at more than 30 d after the booster dose. Protection against severe disease fell from 68.7% (95% CI: 65.9–71.2) at 14–30 d to 41.0% (95% CI: 34.1–47.3) at more than 180 d after the second dose with CoronaVac (Table 4). A marked increase in VE was observed at 14–30 d (89.5%, 95% CI: 83.9–93.1) and over 30 d (89.3%, 95% CI: 78.6–94.7) after administration of the booster dose (Table 4). Waning of protection was also observed for individuals aged 18–59 and 60–79 years, although to a lesser extent, with increases in VE after the booster dose (Tables 3 and 4).

The effectiveness against hospitalization after the primary vaccination series with CoronaVac at 14–30 d after the second dose was 82.1% (95% CI: 81.4–82.8) and 72.4% (95% CI: 70.7–73.9) at more than 180 d after the second dose. Fourteen to 30 d after the BNT162b2 booster dose, this increased to 97.2% (95% CI: 96.0–98.0). Similar results were observed for protection against death.

**Table 2 | Clinical and sociodemographic characteristics of individuals included in a TND analysis by SARS-CoV-2 RT-PCR positivity**

Characteristic	Controls, <i>n</i> = 4,373,385	Cases, <i>n</i> = 3,373,736	Overall, <i>n</i> = 7,747,121
Individuals	4,035,038 (92%)	3,279,280 (97%)	7,314,318 (94%)
Age, years (median IQR)	37 (28, 49)	41 (31, 54)	39 (29, 51)
Sex, female	2,457,036 (56.2%)	1,744,427 (51.7%)	4,201,463 (54.2%)
Race			
White	1,895,837 (43.3%)	1,311,471 (38.9%)	3,207,308 (41.4%)
Black	206,689 (4.7%)	145,220 (4.3%)	351,909 (4.5%)
Asian	74,183 (1.7%)	52,994 (1.6%)	127,177 (1.6%)
Mixed	1,369,960 (31.3%)	1,159,865 (34.4%)	2,529,825 (32.7%)
Indigenous	5,425 (0.1%)	2,698 (0.1%)	8,123 (0.1%)
(Missing)	821,291 (18.8%)	701,488 (20.8%)	1,522,779 (19.7%)
Age group			
18–59	3,838,544 (87.8%)	2,820,645 (83.6%)	6,659,189 (86.0%)
60–79	453,589 (10.4%)	473,094 (14.0%)	926,683 (12.0%)
≥80	81,252 (1.9%)	79,997 (2.4%)	161,249 (2.1%)
Region of residence			
Central West	835,224 (19.1%)	466,542 (13.8%)	1,301,766 (16.8%)
North	208,015 (4.8%)	155,470 (4.6%)	363,485 (4.7%)
Northeast	784,288 (17.9%)	718,474 (21.3%)	1,502,762 (19.4%)
South	330,917 (7.6%)	325,544 (9.6%)	656,461 (8.5%)
Southeast	2,214,941 (50.6%)	1,707,706 (50.6%)	3,922,647 (50.6%)
Pregnancy	47,568 (1.1%)	18,990 (0.6%)	66,558 (0.9%)
Postpartum period	3,429 (0.1%)	2,136 (0.1%)	5,565 (0.1%)
Number of comorbidities			
0	3,921,752 (89.7%)	2,875,746 (85.2%)	6,797,498 (87.7%)
1	346,883 (7.9%)	351,777 (10.4%)	698,660 (9.0%)
≥2	104,750 (2.4%)	146,213 (4.3%)	250,963 (3.2%)
Previous confirmed infection	233,810 (5.3%)	39,593 (1.2%)	273,403 (3.5%)
Vaccination status			
Unvaccinated	2,868,434 (65.6%)	2,661,562 (78.9%)	5,529,996 (71.4%)
CoronaVac	590,266 (13.5%)	322,786 (9.6%)	913,052 (11.8%)
Other vaccines	914,685 (20.9%)	389,388 (11.5%)	1,304,073 (16.8%)
Hospitalization <sup>a</sup>	116,421 (2.7%)	470,541 (14%)	586,962 (7.6%)
Death <sup>a</sup>	30,033 (0.7%)	140,193 (4.2%)	170,226 (2.2%)
Hospitalization or death <sup>a</sup>	119,125 (2.7%)	477,751 (14.2%)	596,876 (7.7%)

IQR, interquartile range; *n* (%). <sup>a</sup>Related to COVID-19 (for cases) and related to other acute respiratory illness (control).

VE against death varied from 82.7% (95% CI: 81.7–83.6) at 14–30 d to 74.8% (95% CI: 72.2–77.2) at more than 180 d after the second dose and increased to 98.3% (95% CI: 96.3–99.2) 14–30 d after the BNT162b2 booster dose. Both hospitalizations and deaths had a similar pattern compared to the composite outcome when stratified by age group (Extended Data Tables 3 and 4).

**Sensitivity analyses.** Given that there was an increase in the use of rapid antigen tests as a diagnostic tool in Brazil, despite its lower accuracy compared to RT–PCR tests, we performed a sensitivity analysis including both diagnostic tests as inclusion criteria. Similar results were obtained when an antigen detection test was used in addition to RT–PCR to define the clinical outcome (Supplementary Table 2). Using rapid antigen plus RT–PCR tests as diagnostic criteria, VE against SARS-CoV-2 infection between 14 and 30 d after the booster was 97.2% (95% CI: 96.0–98.0), which was similar to VE for the main analysis using only RT–PCR

tests in this period. We observed that VE against SARS-CoV-2 infection more than 30 d after the booster was different when comparing rapid antigen plus RT–PCR tests (96.7%, 95% CI: 93.9–98.2) to only RT–PCR (82.6%, 95% CI: 76.9–86.9). This difference when compared to the estimates using RT–PCR alone is likely due to the increase in the sample size (Supplementary Tables 1 and 2).

To untwine the roles of the recent update of booster doses and circulation of the Delta variant, we assessed the additional protection offered by the booster dose compared to individuals who received only two doses of CoronaVac in the period of predominant circulation of the Delta variant (August–November 2021). We evaluated VE at peak response after the booster dose (14–30 d) compared to VE in those who had completed the two-dose CoronaVac immunization regimen more than 180 d beforehand. At 14–30 d after the booster dose, VE against infection was 88.8% (95% CI: 86.3–90.8), and VE against severe outcome was 90.1% (95% CI:

**Table 3 | Effectiveness of CoronaVac vaccine against confirmed SARS-CoV-2 infection, by length of time (in days) since two-dose vaccination or BNT162b2 booster dose, stratified by age group**

Period after vaccine (days)	Overall	18–59	60–79	≥80
<b>Second dose</b>				
0–13	37.9% (36.9–38.8)	43.5% (42.4–44.7)	32.2% (30.1–34.2)	28.3% (23.4–32.9)
14–30	55.0% (54.3–55.7)	56.5% (55.6–57.5)	55.1% (53.7–56.5)	50.3% (46.8–53.6)
31–60	51.7% (51.1–52.4)	52.9% (52.1–53.8)	51.1% (49.7–52.4)	47.0% (43.7–50.1)
61–90	47.6% (46.8–48.3)	48.9% (47.9–49.9)	45.3% (43.6–46.9)	41.0% (37.3–44.4)
91–120	46.1% (45.3–46.9)	52.3% (51.3–53.2)	39.8% (37.8–41.8)	31.8% (27.3–36.1)
121–150	41.8% (40.8–42.8)	50.6% (49.3–51.9)	36.3% (33.8–38.7)	22.1% (16.5–27.3)
151–180	38.0% (36.7–39.3)	44.0% (42.3–45.6)	35.3% (32.2–38.2)	15.1% (8.3–21.5)
>180	34.7% (33.1–36.3)	34.1% (32.2–35.9)	34.5% (29.9–38.7)	10.1% (1.1–18.3)
<b>Booster (BNT162b2)</b>				
0–6	39.6% (33.8–44.8)	40.3% (31.6–47.8)	35.7% (25.2–44.8)	11.5% (–12.4–30.3)
7–13	80.2% (77.0–82.9)	84.6% (80.2–88.0)	75.9% (69.6–80.8)	59.6% (44.9–70.4)
14–30	92.7% (91.0–94.0)	93.5% (90.7–95.5)	93.4% (90.3–95.5)	82.0% (75.0–87.0)
>30	82.6% (76.9–86.9)	61.8% (27.2–79.9)	81.2% (67.6–89.1)	66.4% (49.6–77.5)

**Table 4 | Effectiveness of CoronaVac vaccine against COVID-19 hospitalization or death, by length of time (in days) since two-dose vaccination or BNT162b2 booster dose, stratified by age group**

Period after vaccine (days)	Overall	18–59	60–79	≥80
<b>Second dose</b>				
0–13	65.5% (64.2–66.6)	79.6% (77.6–81.4)	64.5% (62.8–66.1)	51.4% (47.3–55.1)
14–30	82.1% (81.4–82.8)	91.4% (90.3–92.4)	81.6% (80.6–82.5)	68.7% (65.9–71.2)
31–60	82.6% (82.1–83.2)	89.9% (88.9–90.9)	81.4% (80.6–82.2)	66.5% (64.0–68.9)
61–90	80.5% (79.8–81.0)	87.2% (86.0–88.3)	77.6% (76.6–78.6)	63.2% (60.4–65.8)
91–120	78.9% (78.3–79.6)	89.0% (87.8–90.0)	75.5% (74.3–76.7)	58.0% (54.7–61.1)
121–150	77.0% (76.1–77.8)	86.7% (85.2–88.0)	74.9% (73.5–76.3)	52.1% (48.0–55.8)
151–180	75.0% (73.9–76.0)	81.9% (79.8–83.8)	74.7% (72.9–76.4)	47.9% (42.9–52.4)
>180	72.6% (71.0–74.2)	74.8% (72.1–77.2)	72.6% (69.5–75.3)	41.4% (34.5–47.5)
<b>Booster (BNT162b2)</b>				
0–6	80.6% (76.4–84.0)	89.1% (76.6–94.9)	79.6% (73.5–84.2)	48.8% (31.3–61.9)
7–13	91.4% (88.5–93.5)	95.8% (82.9–99.0)	88.3% (83.1–91.8)	78.0% (67.1–85.3)
14–30	97.3% (96.1–98.1)	97.9% (85.0–99.7)	97.1% (94.7–98.5)	89.5% (83.9–93.1)
>30	96.8% (94.1–98.3)	100% (*)	92.0% (79.6–96.9)	89.3% (78.6–94.7)

\*The CI could not be estimated owing to zero/few events in the group.

85.7–93.1), relative to those two-dose CoronaVac vaccinated over 180 d ago (Supplementary Tables 4 and 5).

## Discussion

The overall VE of CoronaVac against confirmed SARS-CoV-2 infection and COVID-19 hospitalization or death waned over time. Protection rebounded, reaching values higher than observed for the two-dose regimen, after a booster dose with BNT162b2. To our knowledge, this is the first study to demonstrate the VE of heterologous prime booster vaccination using an inactivated vaccine and an mRNA vaccine booster.

Our findings on the waning protection of CoronaVac and the effect of a heterologous prime boost dose are consistent with studies evaluating long-term immune responses after inactivated virus vaccines<sup>7,9–11</sup>. Vaccine-induced antibodies declined with time after CoronaVac vaccination<sup>9</sup> and increased when a booster dose of BNT162b complemented the two-dose schedule of inactivated vaccine in humans and in an animal model<sup>11,12</sup>. These findings support the use of an mRNA vaccine booster dose in individuals immunized with two doses of CoronaVac. Other issues, such as the inequity of access to the vaccine and the emergence of new variants, should also be considered in addition to VE when including booster doses in vaccine schedules.

The waning of VE occurred in all age groups but was most evident in the elderly. Similar findings, albeit of different magnitudes, have also been found for BNT162b2 and ChAdOx1 vaccines, and lower VE for the elderly has been previously reported for CoronaVac<sup>3,13–15</sup>.

Immunologic protection markers, such as neutralizing antibodies, were also less frequently detected in older versus younger individuals after vaccination with CoronaVac<sup>16</sup>. As CoronaVac was the first vaccine administered in Brazil, with high uptake in the elderly, there is an over-representation of elderly individuals with longer follow-up. In the present report, although individuals 80 years and older had less than 50% protection against severe COVID-19 5 months after the second CoronaVac dose, VE was over 70% for vaccinees younger than 80 years of age 6 months after the second dose. Considering that older adults are at increased risk of severe outcomes, these results reinforce the necessity of closely monitoring VE for this population.

A strength of our study was the use of large-scale, high-quality, routinely collected real-world data from Brazil. The study used a TND, a design that minimizes bias related to access to healthcare, the occurrence of symptoms and health-seeking behaviors. In Brazil, no specific recommendation was made against testing individuals who were vaccinated. Additionally, similar results were obtained in sensitivity analyses using both RT-PCR and antigen tests, demonstrating the robustness of our findings.

This study has several limitations. First, there was a decrease in transmission rates over time in Brazil, but we adjusted for temporal trends in the analyses. Second, it is possible that changes in viral variants might confound our assessment of VE over time. A stepwise increase in the frequency of Gamma and Delta variants of concern was observed in January–July 2021 and in August–October

2021, respectively, which are included in our study period. An additional effect of the Delta variant in time-dependent waning immunity has been demonstrated after vaccination with two doses of CoronaVac<sup>17</sup>. Third, it is difficult to isolate the performance of one vaccine in a scenario with high uptake of three other vaccines.

In conclusion, we have shown that the VE of the two-dose regimen of CoronaVac against both SARS-CoV-2 infection and COVID-19-related severe outcomes waned for all age groups, particularly in the elderly, and protection increased after a BNT162b2 mRNA booster dose. Our findings provide supportive evidence for a marked increase in protection against both infection and severe outcomes after using a heterologous booster of the BNT162b2 mRNA vaccine in addition to the regular immunization schedule of CoronaVac, especially for older people. A longer follow-up period is necessary to understand how long this level of protection lasts.

### Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-022-01701-w>.

Received: 3 December 2021; Accepted: 14 January 2022;

Published online: 09 February 2022

### References

- Mallapaty, S. et al. How COVID vaccines shaped 2021 in eight powerful charts. *Nature* **600**, 580–583 (2021).
- Jara, A. et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. *N. Engl. J. Med.* **385**, 875–884 (2021).
- Cerqueira-Silva, T. Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: a population-based study. *Lancet Reg. Health Am.* **6**, 100154 (2022).
- Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. *N. Engl. J. Med.* **385**, e85 (2021).
- Andrews, N. et al. Duration of protection against mild and severe disease by Covid-19 vaccines. *N. Engl. J. Med.* <https://doi.org/10.1056/nejmoa2115481> (2022).
- Souza, W. M. et al. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study. *Lancet Microbe* **2**, e527–e535 (2021).
- Medeiros, G. X. et al. Reduced T cell and antibody responses to inactivated coronavirus vaccine among males and individuals above 55 years old. Preprint at *medRxiv* <https://doi.org/10.1101/2021.08.16.21262069> (2021).
- Plano Nacional de Operacionalização da Vacinação Contra a COVID-19 (Ministério da Saúde, 2021); <https://www.gov.br/saude/pt-br/coronavirus/publicacoes-tecnicas/guias-e-planos/plano-nacional-de-vacinacao-covid-19/view>
- Sauré, D. et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. *Lancet Infect. Dis.* **22**, 56–63 (2021).
- Karamese, M. & Tutuncu, E. E. The effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on antibody response in participants aged 65 years and older. *J. Med. Virol.* **94**, 173–177 (2022).
- Zhang, J. et al. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine. *Emerg. Microbes Infect.* **10**, 1598–1608 (2021).
- Keskin, A. U., Bolukcu, S., Ciragil, P. & Topkaya, A. E. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen. *J. Med. Virol.* **94**, 39–41 (2022).
- Ranzani, O. T. et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case–control study. *BMJ* **374**, n2015 (2021).
- Levin, E. G. et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months. *N. Engl. J. Med.* **385**, e84 (2021).
- Katikireddi, S. V. et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. *Lancet* **399**, 25–35 (2022).
- Bichara, C. D. A. et al. Assessment of anti-SARS-CoV-2 antibodies post-Coronavac vaccination in the Amazon region of Brazil. *Vaccines* **9**, 1169 (2021).
- Hunsawong, T. et al. Limited and short-lasting virus neutralizing titers induced by inactivated SARS-CoV-2 vaccine. *Emerg. Infect. Dis.* **27**, 3178–3180 (2021).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022

## Methods

**Study design and data sources.** The TND is a type of case–control study that uses population test results, with the positive tests being the cases and the negative tests being the controls. It is ideally suited to situations where not everyone in a population is being tested, because the factors that influence being tested (health-seeking behavior, access to healthcare, availability of testing, etc.) will apply to both those who test positive and those who test negative<sup>18</sup>. We conducted a TND case–control study to assess VE of the two-dose schedule of CoronaVac over time and the booster dose of BNT162b2 on RT–PCR-confirmed SARS-CoV-2 infection and severe COVID-19 outcomes (hospitalization or death) among adults. From January to November 2021, Gamma and Delta variants circulated in Brazil (Supplementary Fig. 2). The Brazilian Ministry of Health recommends 28 d between the first and second doses of CoronaVac. In the second semester of 2021, a booster dose using BNT162b2, ChAdOx1, Ad26.COV2.S or CoronaVac was recommended 6 months after the second CoronaVac dose<sup>15</sup>, although approximately 92% received BNT162b2 (Supplementary Fig. 3).

We analyzed a deterministically linked dataset comprised of the Programa Nacional de Imunizações, which holds records of all vaccines administered in Brazil (BNT162b2, ChAdOx1, Ad26.COV2.S or CoronaVac); the e-SUS Notifica, which contains records of suspected and confirmed COVID-19 in outpatient clinics; and the Sistema de Informação da Vigilância Epidemiológica da Gripe, which holds records of all COVID-19 hospitalizations and deaths. All data were pseudo-anonymized, with a common unique identifier provided by the Brazilian Ministry of Health (Supplementary Fig. 4). The research protocol was approved by the Brazilian National Commission in Research Ethics (CONEP) (approval no. 4.921.308). Our statistical analysis plan is available at <https://vigivac.fiocruz.br>.

All individuals aged 18 years or older who reported COVID-19-like symptoms and were tested for SARS-CoV-2 between 18 January 2021 and 11 November 2021 were eligible for the study. We excluded: (1) individuals younger than 18 years; (2) individuals who received a different vaccine for the second dose from the first; (3) individuals whose time interval between the first and second doses was fewer than 14 d; (4) tests with missing information of age, sex, city of residence or sample collection date; (5) negative test within 14 d of a previous negative test; (6) negative test followed by a positive test up to 7 d; (7) any test after a positive test up to 90 d; and (8) tests with a symptom onset date greater than notification date (Fig. 1). Cases of confirmed infection were defined as adults with a positive SARS-CoV-2 RT–PCR test and controls with a negative SARS-CoV-2 RT–PCR test, both from a sample collected within 10 d of symptom onset. Cases of COVID-19 hospitalization or death were defined by a positive SARS-CoV-2 test accompanied by hospitalization or death occurring within 28 d of the sample collection date. Controls for the outcome of hospitalization or death were defined based on a negative test.

As a sensitivity analysis, we included SARS-CoV-2 tests based on antigen detection in addition to RT–PCR tests. Antigen test has lower accuracy than RT–PCR test<sup>19</sup>. However, the antigen test has been progressively replacing the RT–PCR test, corresponding to 50.8% of the confirmatory tests for SARS-CoV-2 in the sample population of this study.

**Statistical analysis.** The odds ratio (OR) comparing odds of vaccination between cases and controls and its associated 95% CI were derived using generalized additive logistic regression, adjusting for potential confounders identified from previous literature (age, sex, temporal trends, state of residence, previous infection, pregnancy, postpartum period and comorbidities)<sup>20</sup>. The temporal trend was estimated using the time elapsed, in days, between the study start and the date of symptom onset. Temporal trends and age were modeled as cubic regression spline smooth functions. The comorbidities were cardiac disease, diabetes mellitus, obesity, immunosuppression and chronic kidney disease (categorized in the model as none, one and at least two). VE was estimated as 1–OR and expressed as a percentage. Vaccination status, according to the status at the time of RT–PCR test collection, was classified as unvaccinated and grouped in periods (days) after each dose: first dose (0–6, 7–13 and  $\geq 14$ ), second dose (0–13, 14–30, 31–60, 61–90, 91–120, 121–150, 151–180 and  $> 180$ ) and booster dose (0–6, 7–13, 14–30 and  $> 30$ ). Analyses were also performed stratified by age groups (18–59, 60–79 and  $\geq 80$  years). As sensitivity analysis, we also compared individuals with booster dose against individuals with second dose over 180 d. All data processing and analyses were performed in R (version 4.1.1)<sup>21</sup>, using the following packages: tidyverse<sup>22</sup> and mgcv<sup>23</sup>.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

One of the study coordinators (M.B.-N.) signed a term of responsibility on using each database made available by the Ministry of Health (MoH). Each member of the research team signed a term of confidentiality before accessing the data. Data were manipulated in a secure computing environment, ensuring protection against data leakage. The Brazilian National Commission in Research Ethics approved the research protocol (CONEP approval no. 4.921.308). Our agreement with the MoH for accessing the databases patently denies authorization of access to a third party. Any information for assessing the databases must be addressed to

the Brazilian MoH at <https://datasus.saude.gov.br/>, and requests can be addressed to [datasus@saude.gov.br](mailto:datasus@saude.gov.br). In this study, we used anonymized secondary data following the Brazilian Personal Data Protection General Law, but it is vulnerable to re-identification by third parties as they contain dates of relevant health events regarding the same person. To protect the research participants' privacy, the approved Research Protocol (CONEP approval no. 4.921.308) authorizes the dissemination only of aggregated data, such as the data presented here.

## Code availability

All code used in this study is publicly available at <https://vigivac.fiocruz.br/category/publicacoes.html>.

## References

- Vandenbroucke, J. P. & Pearce, N. Test-negative designs: differences and commonalities with other case–control studies with 'other patient' controls. *Epidemiology* **30**, 838–844 (2019).
- Boum, Y. et al. Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study. *Lancet Infect. Dis.* **21**, 1089–1096 (2021).
- Evaluation of COVID-19 Vaccine Effectiveness: Interim Guidance* (World Health Organization, 2021); [https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine\\_effectiveness-measurement-2021.1](https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1)
- R Core Team R: *A Language and Environment for Statistical Computing* (R Foundation for Statistical Computing, 2021).
- Wickham, H. et al. Welcome to the Tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).
- Wood, S. N. Stable and efficient multiple smoothing parameter estimation for generalized additive models. *J. Am. Stat. Assoc.* **99**, 673–686 (2004).

## Acknowledgements

The present study is part of the Fiocruz VigiVac project on continuous digital evaluation of the national anti-COVID-19 immunization campaign. This study was partially supported by a donation from the 'Fazer o bem faz bem' program. We thank DATASUS for its excellent work in providing unidentified databases. G.L.W., M.L.B. and M.B.-N. are research fellows from CNPq, the Brazilian National Research Council. G.L.W. acknowledges funding from FAPERJ (Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, E-26/210.180/2020). T.C.-S. is a PhD student at the Post-Graduation Program in Health Sciences-UFBA, which is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil, finance code 001. S.V.K. acknowledges funding from a NRS Senior Clinical Fellowship (SCAF/15/02), the Medical Research Council (MC\_UU\_00022/2) and the Scottish Government Chief Scientist Office (SPHSU17). A.S. and C.R. are supported by the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref. MC\_PC\_20058). This partnership between Brazil and Scotland was established through funding from the National Institute for Health Research (GHRG/16/137/99) using UK aid from the UK Government to support global health research.

## Author contributions

V.S.B., M.B.-N., S.V.K. and A.S. conceived the idea for the study. All authors contributed to the study design, with R.F.-O. and T.C.-S. drafting the statistical analysis plan. J.B.J. conducted linkage and data cleaning. T.C.-S. conducted the statistical analysis. N.P., S.V.K. and C.R. oversaw the analysis. V.d.A.O. organized the data linkage. M.B.-N. and M.L.B. secured funding. V.S.B. drafted the manuscript, with assistance from T.C.-S. and E.S.P. All authors critically revised the manuscript and approved the final version for submission.

## Competing interests

S.V.K. was a member of the UK Government's Scientific Advisory Group on Emergencies subgroup on ethnicity and the Cabinet Office's International Best Practice Advisory Group and was co-chair of the Scottish Government's Expert Reference Group on Ethnicity and COVID-19. C.R. reports grants from the Medical Research Council and Public Health Scotland during the conduct of the study and is a member of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group, the Scientific Pandemic Influenza Group on Modelling and the Medicines and Healthcare Products Regulatory Agency Vaccine Benefit and Risk Working Group. A.S. is a member of the Scottish Government Chief Medical Officer's COVID-19 Advisory Group and its Standing Committee on Pandemics. A.S. is also a member of the UK Government's New and Emerging Respiratory Virus Threats Risk Stratification Subgroup. V.d.A.O., V.S.B., M.L.B. and M.B.-N. are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for the public health service use. All other authors declare no competing interests.

**Additional information**

**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-022-01701-w>.


**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-022-01701-w>.

**Correspondence and requests for materials** should be addressed to Viviane S. Boaventura.


**Peer review information** *Nature Medicine* thanks Ben Lopman and Brendan Flannery for their contribution to the peer review of this work. Saheli Sadanand was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).







**Extended Data Fig. 1** | Cases of infection by SARS-CoV-2 from February 2020 to November,11 2021, by week.




**Extended Data Fig. 2 |** Distribution of hospitalization due to COVID-19 from February 2020 to November 11, 2021, by week.




**Extended Data Fig. 3 |** Distribution of deaths due to COVID-19 from February 2020 to November 11, 2021, by week.



**Extended Data Fig. 4** | Distribution of severe outcomes due to COVID-19 from February 2020 to November 11, 2021, by week.



**Extended Data Fig. 5 |** Distribution of time between booster dose and symptom onset, in days, by age group.



**Extended Data Fig. 6** | Distribution of time elapsed between second dose and booster dose in the population of study.

**Extended Data Table 1 | Number of SARS-CoV-2 infection and total of tests of individuals categorized as unvaccinated and vaccinated with CoronaVac**

Vaccination Status	Overall		18-59		60-79		≥80	
	Cases	Total	Cases	Total	Cases	Total	Cases	Total
Unvaccinated	2,661,562 (48.1%)	5,529,996	2,381,281 (47.0%)	5,064,383	259,065 (60.4%)	428,949	21,216 (57.9%)	36,664
First dose								
0-6	25,403 (48.9%)	51,937	12,416 (38.8%)	31,986	11,076 (65.7%)	16,865	1,911 (61.9%)	3,086
7-13	28,579 (49.7%)	57,523	13,748 (39.7%)	34,654	12,300 (64.7%)	19,016	2,531 (65.7%)	3,853
≥14	57,671 (39.4%)	146,423	26,882 (29.9%)	89,768	24,715 (53.6%)	46,111	6,074 (57.6%)	10,544
Second dose								
0-13	28,666 (38.3%)	74,750	13,585 (29.0%)	46,799	11,979 (52.9%)	22,652	3,102 (58.5%)	5,299
14-30	25,134 (31.2%)	80,547	12,232 (23.9%)	51,161	10,430 (43.0%)	24,235	2,472 (48.0%)	5,151
31-60	40,989 (32.9%)	124,552	17,884 (24.8%)	72,044	18,948 (43.5%)	43,555	4,157 (46.4%)	8,953
61-90	35,515 (33.8%)	105,148	15,577 (27.8%)	56,071	15,062 (38.6%)	39,071	4,876 (48.7%)	10,006
91-120	30,694 (32.1%)	95,529	13,297 (26.6%)	50,015	13,273 (36.6%)	36,309	4,124 (44.8%)	9,205
121-150	22,189 (30.7%)	72,231	8,153 (22.7%)	35,863	10,583 (38.1%)	27,805	3,453 (40.3%)	8,563
151-180	15,819 (28.8%)	54,947	6,102 (20.7%)	29,535	6,919 (37.4%)	18,517	2,798 (40.6%)	6,895
>180	11,066 (26.6%)	41,602	7,353 (23.6%)	31,132	2,029 (33.8%)	5,999	1,684 (37.7%)	4,471
Booster dose w/BNT162b2								
0-6	690 (25.8%)	2,672	276 (19.0%)	1,450	288 (32.9%)	875	126 (36.3%)	347
7-13	212 (10.0%)	2,117	66 (5.5%)	1,206	91 (14.4%)	630	55 (19.6%)	281
14-30	103 (4.0%)	2,552	31 (2.3%)	1,345	29 (4.2%)	691	43 (8.3%)	516
>30	56 (10.7%)	522	11 (12.9%)	85	15 (10.5%)	143	30 (10.2%)	294

**Extended Data Table 2 | Number of COVID-19 hospitalization or death and total of individuals in unvaccinated and CoronaVac vaccinees**

Vaccination Status	Overall		18-59		60-79		≥80	
	Cases	Total	Cases	Total	Cases	Total	Cases	Total
Unvaccinated	343,414 (10.7%)	3,211,848	233,944 (8.0%)	2,917,046	96,038 (36.1%)	265,922	13,432 (46.5%)	28,880
First dose								
0-6	6,982 (20.8%)	33,516	1,255 (6.0%)	20,825	4,632 (44.4%)	10,421	1,095 (48.2%)	2,270
7-13	7,328 (20.2%)	36,272	1,265 (5.7%)	22,171	4,737 (41.4%)	11,453	1,326 (50.1%)	2,648
≥14	13,437 (13.1%)	102,189	1,630 (2.5%)	64,516	8,515 (28.5%)	29,911	3,292 (42.4%)	7,762
Second dose								
0-13	5,816 (11.2%)	51,900	527 (1.6%)	33,741	3,718 (25.8%)	14,391	1,571 (41.7%)	3,768
14-30	4,259 (7.1%)	59,672	278 (0.7%)	39,207	2,754 (16.6%)	16,559	1,227 (31.4%)	3,906
31-60	7,706 (8.4%)	91,269	474 (0.9%)	54,634	5,180 (17.4%)	29,787	2,052 (30.0%)	6,848
61-90	7,904 (10.2%)	77,537	516 (1.3%)	41,010	4,858 (16.8%)	28,867	2,530 (33.0%)	7,660
91-120	7,614 (10.5%)	72,449	452 (1.2%)	37,170	4,840 (17.4%)	27,876	2,322 (31.4%)	7,403
121-150	6,650 (11.7%)	56,692	380 (1.4%)	28,090	4,152 (19.4%)	21,374	2,118 (29.3%)	7,228
151-180	4,848 (11.0%)	43,976	370 (1.6%)	23,803	2,661 (18.7%)	14,259	1,817 (30.7%)	5,914
>180	2,376 (7.2%)	32,912	488 (2.0%)	24,267	746 (15.8%)	4,716	1,142 (29.1%)	3,929
Booster dose w/BNT162b2								
0-6	165 (7.7%)	2,147	7 (0.6%)	1,181	83 (12.4%)	670	75 (25.3%)	296
7-13	70 (3.5%)	1,975	2 (0.2%)	1,142	37 (6.4%)	576	31 (12.1%)	257
14-30	37 (1.5%)	2,486	1 (0.1%)	1,315	11 (1.6%)	673	25 (5.0%)	498
>30	14 (2.9%)	480	0 (0.0%)	74	5 (3.8%)	133	9 (3.3%)	273



**Extended Data Table 3 | Vaccine effectiveness against hospitalisation due to COVID-19 using RT-PCR, by length of time (in days) since two-dose vaccination or BNT162b2 booster dose**

Period post vaccine (days)	Overall	18-59	60-79	≥80
<b>Second dose</b>				
0-13	65.5% (64.3-66.7)	79.4% (77.5-81.2)	64.4% (62.7-66.0)	51.0% (46.9-54.9)
14-30	82.1% (81.4-82.8)	91.4% (90.3-92.4)	81.4% (80.5-82.4)	68.4% (65.5-71.0)
31-60	82.6% (82.0-83.1)	90.0% (89.0-90.9)	81.2% (80.3-82.0)	66.0% (63.4-68.5)
61-90	80.4% (79.8-81.0)	87.2% (85.9-88.3)	77.5% (76.4-78.5)	62.8% (60.0-65.5)
91-120	78.7% (78.0-79.4)	88.9% (87.8-90.0)	75.3% (74.0-76.4)	57.1% (53.6-60.3)
121-150	76.7% (75.9-77.5)	86.6% (85.0-87.9)	74.8% (73.3-76.2)	51.2% (47.0-55.0)
151-180	74.7% (73.6-75.8)	81.9% (79.7-83.8)	74.5% (72.7-76.2)	47.0% (42.0-51.7)
>180	72.4% (70.7-73.9)	74.7% (72.0-77.2)	72.3% (69.2-75.1)	41.0% (34.0-47.3)
<b>Booster (BNT162b2)</b>				
0-6	80.3% (76.0-83.8)	89.0% (76.5-94.9)	79.3% (73.1-84.0)	48.4% (30.6-61.6)
7-13	91.2% (88.3-93.4)	95.8% (82.8-99.0)	88.0% (82.7-91.6)	78.1% (67.0-85.4)
14-30	97.2% (96.0-98.0)	97.9% (84.9-99.7)	97.1% (94.6-98.4)	89.2% (83.4-92.9)
>30	96.7% (93.9-98.2)	100% (*)	91.8% (79.0-96.8)	89.0% (78.0-94.5)

The confidence interval could not be estimated due to zero/few events in the group

**Extended Data Table 4 | Vaccine effectiveness against death due to COVID-19 using RT-PCR, by length of time (in days) since two-dose vaccination or BNT162b2 booster dose**

Period post vaccine (days)	Overall	18-59	60-79	≥80
<b>Second dose</b>				
0-13	67.3% (65.6-68.9)	86.4% (82.5-89.4)	69.6% (67.6-71.6)	56.0% (51.6-60.0)
14-30	82.7% (81.7-83.6)	91.4% (88.7-93.5)	84.5% (83.3-85.6)	72.7% (69.8-75.4)
31-60	83.6% (82.8-84.3)	91.9% (89.7-93.6)	84.8% (83.8-85.7)	70.0% (67.2-72.5)
61-90	81.4% (80.5-82.2)	92.2% (89.8-94.0)	82.5% (81.3-83.7)	67.2% (64.2-69.9)
91-120	79.8% (78.7-80.8)	95.0% (93.1-96.4)	81.7% (80.3-83.0)	63.5% (59.9-66.7)
121-150	78.3% (77.0-79.6)	93.7% (90.9-95.7)	82.0% (80.3-83.5)	58.7% (54.3-62.7)
151-180	76.8% (75.1-78.4)	92.1% (88.2-94.7)	81.9% (79.7-83.8)	53.9% (48.3-58.9)
>180	74.8% (72.2-77.2)	90.3% (85.5-93.5)	81.5% (77.6-84.7)	45.5% (37.1-52.8)
<b>Booster (BNT162b2)</b>				
0-6	80.3% (73.1-85.6)	100% (*)	81.4% (71.3-87.9)	59.9% (39.3-73.5)
7-13	92.2% (87.4-95.2)	100% (*)	92.3% (83.8-96.3)	80.7% (65.3-89.2)
14-30	98.3% (96.3-99.2)	81.9% (-31.6-97.5)	99.1% (93.6-99.9)	95.4% (88.7-98.1)
>30	97.1% (90.5-99.1)	100% (*)	94.3% (58.3-99.2)	93.5% (73.2-98.4)

The confidence interval could not be estimated due to zero/few events in the group

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection R version 4.1.1

Data analysis R version 4.1.1; packages: mgcv version 1.8-36; tidyverse version 1.3.1

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

One of the study coordinators (MB-N) signed a term of responsibility on using each database made available by the Ministry of Health (MoH). Each member of the research team signed a term of confidentiality before accessing the data. Data was manipulated in a secure computing environment, ensuring protection against data leakage. The Brazilian National Commission in Research Ethics approved the research protocol (CONEP approval number 4.921.308). Our agreement with MoH for accessing the databases patently denies authorization of access to a third party. Any information for assessing the databases must be addressed to the Brazilian MoH at <https://datasus.saude.gov.br/>, and requests can be addressed to [datasus@saude.gov.br](mailto:datasus@saude.gov.br). Herein we used anonymized secondary data following the Brazilian Personal Data Protection General Law (LGPD), but it is vulnerable to re-identification by third parties, as they contain dates of relevant health events regarding the

same person. To protect the research participants' privacy, the approved Research Protocol (CONEP approval number 4.921.308) authorizes only the dissemination of aggregated data, such as the data presented here.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Given that the sample sizes were based on national linked datasets with our sample size only excluding individuals that do not fit the eligibility criteria, the sample size for each sub-study can be considered sufficient. Of 7,314,318 individuals tested between January 18, 2021 and November 11, 2021.
Data exclusions	We excluded: (i) individuals younger than 18 years; (ii) individuals who received a different vaccine for the second dose from the first; (iii) individuals whose time interval between the first and second doses was less than 14 days; (iv) tests with missing information of age, sex, city of residence or sample collection date; (v) negative test within 14 days of a previous negative test; (vi) negative test followed by a positive test up to 7 days; (vii) any test after a positive test up to 90 days; (viii) tests with a symptom onset date greater than notification date
Replication	For replication, additional analyses were conducted to estimate vaccine effectiveness: using rapid antigen test in addition to RT-PCR test as diagnostic criteria and using the using as comparison group individuals with more than 180 days post second dose of CoronaVac. All analyses confirmed/reproduced estimates of vaccine effectiveness obtained in the main analysis.
Randomization	Not applicable (this is an observational study)
Blinding	Not applicable (this is an observational study)

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging